Muscle power is essential – always and everywhere.

Our muscles allow us to laugh and hug each other. Without them, we cannot walk, lift a cup, swallow, or even breathe.

Major loss of muscle function forces patients out of work and leaves them facing continuously decreasing quality of life and premature death. Muscle impairment can be a result of congenital malformation, trauma, hereditary muscular dystrophies, acute and/or critical conditions including cancer, or ageing.

Until today, most patients with muscle disorders are treated with palliative medicine.

MyoPax is dedicated to radically improving this landscape. We aim to restore muscle function in local defects and muscle wasting disorders by delivering effective muscle regeneration therapies.

Vanguard stem cell manufacturing, cell engineering and gene-editing technologies are the pillars of our nascent product platforms.

MyoPax is a spin-off from the Muscle Research Unit of the Charité Universitätsmedizin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association in Berlin (Website: Muscle Research Unit). Upon its launch in 2022, MyoPax joined the BioInnovation Institute in Copenhagen. We envisage becoming the international leader in biological muscle therapy.

We have more than 30 years of relevant experience in human skeletal muscle research and development. We are passionate about our mission and determined to succeed. We are empowered by strong science, state-of-the-art technology and preeminent clinical expertise. 

Now we are combining these strengths to return muscle power to those who need it.  Join us.

Severe muscle disorders

More than 30 million people suffer from severe muscle disorders in the EU and US alone. The current standard of care is palliative treatment in the form of artificial ventilation, physiotherapy, or surgery. Severe muscle diseases include local muscle defects, hereditary muscular dystrophies, and secondary muscle wasting in the context of other acquired diseases.

Local muscle defects are caused by trauma, surgery or prenatal malformations and can have a significant impact on patients’ lives. A defect in the bladder sphincter muscle can lead to life-long urinary incontinence; defects in the diaphragm to the inability to breathe without artificial ventilation.

Muscular dystrophies comprise more than 50 different diseases. They are caused by mutations in specific genes that are the blueprint for proteins relevant to muscle function. Mutations are either inherited or may occur spontaneously. The disease courses are clinically heterogeneous, leading to progressive weakening and degradation of skeletal muscle over time. The diseases differ in terms of which muscles are primarily affected, and when symptoms appear.

Secondary muscle wasting occurs in the context of other diseases and worsens the prognosis of the primary disease. Cachexia (secondary muscle wasting) is caused by diseases such as cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and infectious diseases. Sarcopenia is muscle atrophy that occurs with aging. It leads to reduced quality of life, falls, fractures, and disability.